1597 results about "Histone protein" patented technology

The invention discloses a phytophthora plant pathogenic oomycete histone lysine methyl transfer protein as well as a coding gene and application thereof. Wherein the phytophthora sojae histone lysine methyltransferase KMT3-1 is as shown in a sequence 2 in the specification, and the phytophthora sojae histone lysine methyltransferase KMT3-1 is as shown in a sequence 2 in the specification; the coding gene is shown as a sequence 1. Experiments prove that the KMT3-1 protein plays an important role in the growth and development process of phytophthora sojae, specifically, after the protein is deleted, the growth rate of phytophthora hyphae is slowed down, the sporangium yield is remarkably reduced, the release of zoospores is stopped, the oospore yield is reduced, the pathogenicity is reduced, and the like. Corresponding histone methyltransferase inhibitors have different degrees of activity on typical plant pathogenic oomycetes such as phytophthora sojae, phytophthora capsici and phytophthora infestans. The gene provided by the invention has great application potential in the aspect of preventing and controlling the crop epidemic diseases caused by phytophthora plant pathogenic oomycetes, and a novel bactericide developed on the basis of the protein as an action target has important practical significance in controlling the occurrence and prevalence of the crop epidemic diseases caused by phytophthora.

Recombinant NK cells, and especially recombinant NK-92 cells express a chimeric antigen receptor (CAR) having an intracellular domain of FcεRIγ. Notably, CAR constructs with an intracellular domain of FcεRIγ had a substantially prolonged duration of expression and significantly extended cytotoxicity over time. The CAR may be expressed from RNA and DNA, preferably as a tricistronic construct that further encodes CD16 and a cytokine to confer autocrine growth support. Advantageously, such constructs also enable high levels of transfection and expression of the recombinant proteins and provide a convenient selection marker to facilitate rapid production of recombinant NK / NK-92 cells.

The invention provides an application of a lactic acid modified histone H3 in preparation of a product for treating and / or preventing lung microvascular endothelial cell dysfunction, and the lactic acid modified histone H3 is obtained by carrying out lactic acid modification on the 14th amino acid of histone, the lung microvascular endothelial cell dysfunction is sepsis mediated lung microvascular endothelial cell dysfunction. The invention provides a new idea for the treatment of sepsis-mediated lung microvascular endothelial cell dysfunction.

The present disclosure relates to compounds, compositions and methods for treating diseases or conditions mediated by aberrant histone deacetylase 8 (HDAC8) activity. In some embodiments, the disclosed compounds comprise an HDAC8 targeting ligand TL moiety covalently linked to a degradation determinant moiety that recruits E3 ubiquitin ligase to HDAC8. In some embodiments, the degradation determinant can bind to an E3 ligase, which is a von Hippel-Lindau (VHL) tumor suppressor, and the E3 ligase can bind to an E3 ligase, which is a Von Hippel-Lindau (VHL) tumor suppressor.

The invention belongs to the technical field of biological medicines, and discloses a recombinant protein and application thereof in preparation of fish vaccines. According to the invention, CP4 protein of nervous necrosis virus of grouper is taken as antigen for vaccine, recombinant Escherichia coli BL21 (pET32a-CP4) capable of expressing the protein is constructed by means of genetic engineering technology, recombinant protein rCP4 is obtained through induced expression, and oxidized single-walled carbon nanotubes are taken as carriers to prepare the grouper immersion vaccine (namely SWCNT-rCP4 vaccine). According to the SWCNT-rCP4 vaccine provided by the invention, the immunization of the grouper can be realized through soaking immunization, the survival rate of the grouper reaches 85% after the grouper is soaked and immunized for 4w and then is infected with NNV, and the immune protection effect is remarkable.

The invention discloses preparation of a human CD56 immune phage display antibody library, which comprises the following steps: S1, animal immunization: expressing recombinant hCD56 protein in escherichia coli, then immunizing a Balb / c mouse, and detecting immune titer; s2, splenocyte preparation: extracting RNA (Ribonucleic Acid) of immune mouse spleen cells, and performing reverse transcription to obtain cDNA (Complementary Deoxyribonucleic Acid); s3, preparation of an initial bacteriophage display library: amplifying a heavy chain variable region and a light chain variable region by using a PCR technology, and then assembling to form scFv; constructing scFv phagocytids, electrically transforming the scFv phagocytids into TG1 competent cells, and constructing a bacterial library; s4, constructing a phage single-chain library of the hCD56: infecting the bacterial library by using a helper phage M13K07, and constructing a phage single-chain antibody library; and S5, elutriation and screening of a phage library: specifically enriching a phage single-chain antibody library, screening positive clones from the phage single-chain antibody library, and determining a sequence. According to the invention, the human hCD56 antibody scFv sequence fragment can be screened out, and the research and development period is shortened.

The invention relates to a plant non-histone lysine crotonylation site identification method and a plant non-histone lysine crotonylation site identification system. The method comprises the following steps: extracting non-histone lysine crotonylation Kcr sites from a protein sequence to form a data set; extracting a first feature vector by using a self-attention mechanism and a smoothing function through a protein language model ESM2; capturing a long-distance dependency relationship and context information in the protein sequence through a bidirectional long-short-term memory network, and extracting a second feature vector; and carrying out feature fusion processing and then carrying out classification prediction to obtain a Kcr site identification result. By constructing a protein sequence data set, ESM2 utilizes a self-attention mechanism and a smoothing function, and BiLSTM captures a long-distance dependency relationship and context information in the protein sequence, efficient feature extraction of the protein sequence is realized, and more comprehensive information can be provided through fusion processing, so that the detection precision of Kcr site detection and recognition is improved.

The present invention relates to a respiratory syncytial virus subtype B (RSV-B) recombinant F protein, a polynucleotide encoding the same, a nucleic acid construct comprising the polynucleotide, an expression vector comprising the nucleic acid construct, a host cell wherein the polynucleotide, the nucleic acid construct or the expression vector is transformed or transfected, a stabilized trimer formed therefrom, and a method for preparing the same. An immunogenic composition comprising any of the foregoing, and its use in the preparation of a vaccine for the prevention and / or treatment of respiratory syncytial virus infection. The RSV-B recombinant F protein comprises at least one specific epitope of the pre-fusion F protein, a stable F protein tripolymer with pre-fusion conformation can be formed, the expression is stable, the form is uniform, and the yield is greatly improved; the formed F protein trimer has good immunogenicity, can stimulate an organism to generate high-level antibody titer, and has great significance in clinical treatment and prevention and control of the respiratory syncytial virus.

The invention provides a subunit vaccine for resisting poultry clostridium perfringens, which is characterized in that CPA and NetB proteins are truncated, and three gene sequences of auxiliary protease Fba are connected in series and fused through Linker to obtain recombinant protein. Immunogenicity detection on the N-C-F recombinant protein finds that the N-C-F recombinant protein can induce SPF chicken to generate antibodies. Immune protection test results show that the subunit vaccine prepared from the N-C-F protein and the adjuvant can achieve 100% immune protection effect when being used for immunizing 100 [mu] g / chicken and 200 [mu] g / chicken, and the subunit vaccine can be used as a subunit vaccine for resisting various toxin types.

The invention discloses an indirect ELISA kit for rapidly detecting a porcine epidemic diarrhea virus IgA antibody and application of the indirect ELISA kit, and belongs to the technical field of immunology. The invention provides a recombinant PEDV-RBD protein. The amino acid sequence of the recombinant PEDV-RBD protein is shown as SEQ ID NO. 3. The indirect ELISA kit for detecting the porcine epidemic diarrhea virus IgA antibody is constructed based on the recombinant PEDV-RBD protein, the PEDV IgA antibody in pig breast milk or serum can be accurately captured for detection, the kit has the advantages of high sensitivity and strong specificity, and a technical means is provided for prevention and control of porcine epidemic diarrhea.

The invention belongs to the technical field of biomedicine, and discloses application of histone lactic acid modification as a target spot in preparation of a medicine for preventing or treating chronic obstructive pulmonary diseases, in particular to lactic acid modification on 18th lysine residues of histone 3, and the expression level of ATM protein in airway epithelial cells is up-regulated through the histone lactic acid modification, so that the chronic obstructive pulmonary diseases can be prevented or treated. The expression of cell senescence key genes is promoted, so that the senescence phenotype of airway epithelial cells is aggravated, and the airway epithelial cells participate in the disease process of mediating the chronic obstructive pulmonary disease. The discovery provides a new therapeutic target for the chronic obstructive pulmonary disease.

The invention relates to a sulfonyl compound and a pharmaceutical composition and application thereof. The sulfonamide compound comprises a compound as shown in formula I: # imgabs0 #. The sulfonamide compound has a benzyne structure located on the left side of sulfonyl and a pyridino isoxazole structure located on the right side of sulfonyl. Through the synergistic effect of sulfonyl, a benzyne structure and a pyridoisoxazole structure, the druggability of the compound and the capability of competitively combining with acetyl coenzyme to KAT6A / KAT6B can be remarkably improved, the acetyl coenzyme is inhibited from combining with KAT6A / KAT6B to catalyze histone related sites, and gene expression inducing cancer cell growth is prevented; further, the KAT6A / KAT6B gene can be used for treating related tumor diseases caused by KAT6A / KAT6B gene amplification or KAT6A / KAT6B protein overexpression.

The invention discloses a preparation method of high-purity recombinant mussel mucoprotein, and belongs to the technical field of recombinant protein preparation, the idea of improving target protein expression by adopting fusion protein is adopted, and fusion expression is performed on partial peptide fragments of an amino acid sequence of mytilus coruscus Mfp-3 and an amino acid sequence of common mussel preCol-D to obtain the high-purity recombinant mussel mucoprotein. The recombinant mussel mucin which is high in purity, low in endotoxin content and good in adhesion performance is obtained by combining improvement of induction, tyrosinase modification and separation and purification processes, a new thought is provided for industrial production of the recombinant mussel mucin through successful preparation of the recombinant mussel mucin, raw material support is provided for multi-field application of the recombinant mussel mucin, and the method is suitable for industrial production of the recombinant mussel mucin. The customized sequence recombinant mussel mucoprotein is prepared according to application requirements, and the application of the mussel mucoprotein in different fields is promoted.

The present invention belongs to the field of biotechnology, and specifically relates to an antibody targeting CD47 and its application. The anti-human CD47 antibody provided by the present invention can effectively bind to recombinant CD47 protein, block the binding of CD47 to its biological ligand SIRPa, and effectively identify and bind to CD47 positive tumor cells. At the same time, the CD47 antibody does not cause significant hemagglutination reaction and red blood cell binding of human red blood cells at high concentrations.

The invention relates to a repetitive structural unit recombinant protein cpE2 and a preparation method and application thereof. The recombinant protein cpE2 of the repetitive structural unit has self-assembly performance and is formed by modifying an E2 subunit of a pyruvate dehydrogenase compound and dihydrofatty acid amide transacetylase. Specifically, the C end of the E2 protein is arranged at the N end through a connecting peptide by utilizing a circulating recombination principle, so that the recombinant protein cpE2 is constructed. The engineered cpE2 protein cage can be self-assembled into a cage-shaped structure, linking groups can be respectively brought into the protein cage through N-terminal or C-terminal modification of cpE2, the problem that a modifier or a drug is difficult to put into the protein cage by a traditional E2 protein is solved, meanwhile, the specific particle size of the cpE2 protein cage can be controlled through the length of a linking peptide, and the protein cage has a good application prospect. And efficient carrying of goods is achieved.

The invention provides application of lactic acid modified histone H3 in preparation of drugs and / or diagnostic kits for preventing and / or treating pancreatic ductal adenocarcinoma, and belongs to the technical field of disease diagnosis and / or treatment. The invention provides application of a lactic acid modified histone H3 as a target spot in preparation of a pancreatic ductal adenocarcinoma diagnostic kit or a medicine for preventing and / or treating pancreatic ductal adenocarcinoma. The site of lactic acid modification is 23-site lysine. The expression of H3K23la detected in clinical sample tissues in pancreatic ductal adenocarcinoma tumor tissues is obviously higher than that in para-carcinoma normal tissues, overexpression and non-expression of H3K23la in cells are regulated and controlled through in-vitro experiments in combination with overexpression and knock-down technologies, and results show that proliferation, invasion and migration capacities of pancreatic ductal adenocarcinoma cells are remarkably inhibited, so that the pancreatic ductal adenocarcinoma cells are remarkably inhibited. Therefore, the H3K23la can be used as a target spot for diagnosis and treatment of the pancreatic duct adenocarcinoma, and has wide application in diagnosis or treatment of the pancreatic duct adenocarcinoma.

The present invention provides a monkey serum amyloid A recombinant protein, a monoclonal antibody and a preparation method and application thereof, wherein the amino acid sequence of the recombinant protein is shown in SEQ ID No. 1, and the nucleotide sequence encoding the recombinant protein is shown in SEQ ID No. 2. By optimizing the antigen peptide sequence and the expression vector, the efficient and soluble expression of monkey serum amyloid A in Escherichia coli is achieved, and a mouse monoclonal antibody specifically binding to monkey serum amyloid A is screened based on the monkey serum amyloid A recombinant protein, and the above mouse monoclonal antibody is used to screen a pairable monoclonal antibody, and further based on the monoclonal antibody combination, a double antibody sandwich immune ELISA detection method or kit applied to monkey serum amyloid A recombinant protein is obtained, which has high detection sensitivity and can be well applied to the detection of monkey serum.

The invention discloses a method for constructing recombinant hansenula polymorpha for efficiently producing canine serum albumin and an expression method of the recombinant hansenula polymorpha. Based on a natural sequence of a canine serum albumin gene, a codon of the canine serum albumin gene is optimized, so that the canine serum albumin gene is more suitable for being expressed in hansenula polymorpha, an optimal promoter of the sequence expressed in hansenula polymorpha is further screened, and the copy number of the canine serum albumin in hansenula polymorpha is optimized. The yield of the canine serum albumin hansenula polymorpha strain obtained by recombinant transformation can reach 0.8-0.9 g / L after 6 days of high-density fermentation production in a fermentation tank.

The invention belongs to the field of veterinary drugs, and relates to an avian infectious bronchitis virus antigen recombinant protein S-Trimer and a subunit vaccine thereof. The invention provides an avian infectious bronchitis virus antigen recombinant protein S-Trimer. The amino acid sequence of the antigen recombinant protein S-Trimer is as shown in SEQ ID No. 4. The invention provides an infectious bronchitis virus antigen. The infectious bronchitis virus antigen is of a trimer structure of the recombinant protein S-Trimer. The invention provides a chicken infectious bronchitis virus subunit vaccine. The subunit vaccine comprises a pharmaceutically acceptable carrier and an immune dose of the chicken infectious bronchitis virus antigen. The vaccine is high in safety, good in immunogenicity and stable in batches, and can provide complete protection for attacking the infectious bronchitis virus.

The invention discloses a pertussis recombinant protein and a monoclonal antibody and application thereof.The pertussis recombinant protein is synthesized by selecting an S1 subunit of pertussis PT and a part of sequences of FHA protein, the pertussis recombinant protein is expressed through a prokaryotic expression system and purified, the protein serves as an antigen to immunize a mouse, and the pertussis recombinant protein is obtained. Positive hybridoma cell strains 3B10, 3D9 and 5F7 capable of stably secreting the antibody are obtained by adopting a hybridoma technology, the preservation numbers are respectively CCTCC NO: C202567, CCTCC NO: C202568 and CCTCC NO: C202569, and the obtained monoclonal antibody has relatively high affinity and detection sensitivity to pertussis PT and FHA recombinant proteins, is used for detecting a bordetella pertussis antigen, is strong in specificity and high in sensitivity, can be used for instant detection, and can be applied to clinical application. And the method has a relatively high application value.

The invention belongs to the technical field of genetic engineering, and discloses application of FGF8 protein in preparation of an antibacterial agent. Escherichia coli BL21 (DE3) is adopted to express grass carp FGF8a and mouse FGF8b, the grass carp FGF8a and mouse FGF8b recombinant protein is obtained after purification of a Ni < 2 + >-TED agarose gel column, and it is found that the two proteins have the remarkable sterilization effect on gram-negative bacteria and gram-positive bacteria, can be used for preparing broad-spectrum antibacterial agents or antibacterial drugs and have high application value.

The invention provides a novel three-antigen HSV-2 adjuvant subunit vaccine as well as a preparation method and application thereof. The vaccine comprises herpes simplex virus recombinant protein and a composite adjuvant, the herpes simplex virus recombinant protein comprises extracellular domains of three proteins, namely HSV-2gE, gD and gC, wherein the amino acid sequences of the extracellular domains of the HSV-2gE, the gD and the gC are respectively shown as SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3; and the composite adjuvant is composed of CpG oligodeoxynucleotide and QS-21. Experiments prove that by adding the composite adjuvant composed of CpG oligodeoxynucleotide and QS-21, the immunogenicity, in-vivo protectiveness, virus removal and other immune functions of the HSV-2 subunit vaccine can be remarkably improved; meanwhile, the vaccine is a cross immune protection vaccine of an HSV-2 virus strain and an HSV-1 virus strain.

The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.

The invention relates to the technical field of biology, and particularly discloses a recombinant protein for improving the curative effect of an ADC drug and application of the recombinant protein. The recombinant protein comprises a tumor cell surface targeting structure, a cell transmembrane structure and toxin molecules, the toxin molecule is connected and fused with the tumor cell surface targeting structure and / or the cell transmembrane structure; the tumor cell surface targeting structure is a protein structure capable of being specifically combined with a tumor cell surface target spot; and the cell penetrating structure is a protein structure for mediating the recombinant protein to penetrate through a cell membrane to enter the cell. The tumor cell surface targeting structure is used for specifically recognizing a target cell surface target spot, the killing activity of a conventional antibody is brought into play, then toxin molecules are brought into tumor cells through the cell transmembrane structure, toxin is released, the tumor killing effect is achieved, the ADC drug curative effect is improved, and the ADC drug application prospect is wide. The transmembrane efficiency of the cell transmembrane structure can be improved to 50-90%, so that the traditional ADC drug treatment window is improved.

The invention provides a classical swine fever virus subunit vaccine and a preparation method thereof, the classical swine fever virus subunit vaccine is based on an E2 protein gene and a GP67 signal peptide gene of a CSFV 1.1 strain, a recombinant expression vector is constructed through gene cloning, a classical swine fever virus E2 recombinant protein is obtained through expression of an insect baculovirus system, and the classical swine fever virus subunit vaccine is obtained. And the recombinant protein is combined with a colloidal manganese adjuvant to prepare the swine fever virus subunit vaccine. The hog cholera virus E2 recombinant protein is close to natural E2 protein in structural function, high in reduction degree, high in expression quantity and suitable for vaccine production and application; the vaccine can generate specific humoral immunity and relatively strong cellular immunity, and is beneficial to removal of CSFV in an animal body; meanwhile, the vaccine can be distinguished from attenuated vaccine strain immunization or wild strain infection at the nucleic acid level, can be used for preventing and purifying classical swine fever in an intensive pig farm, and has a considerable application prospect.

Disclosed herein are CRISPR / Cas9-based gene activation systems that include a fusion protein of a Cas9 protein and a protein having histone acetyltransferase activity, and methods of using said systems.

The invention relates to the technical field of biological medicine, in particular to application of ADAMTS13 to occlusive cardiovascular and cerebrovascular diseases. On one hand, the invention provides the biomarker ADAMTS13 for establishing the collateral circulation of the patient suffering from the occlusive cardiovascular and cerebrovascular diseases, and the biomarker ADAMTS13 can be used as a target spot for diagnosing, preventing and treating the occlusive cardiovascular and cerebrovascular diseases and can effectively predict the establishment of the collateral circulation of the patient suffering from the occlusive cardiovascular and cerebrovascular diseases and prevent the development of adverse cardiovascular events; the method has important value on clinical cardiovascular events, and can improve the survival rate of patients with occlusive vascular diseases and improve long-term prognosis; on the other hand, the invention provides an ADAMTS13 recombinant protein, the amino acid sequence of which is as shown in SEQ ID No: 1, and the ADAMTS13 recombinant protein can improve the proliferation, migration, invasion and tube forming capabilities of endothelial cells, and has important clinical application value for developing drugs for preventing and / or treating occlusive cardiovascular and cerebrovascular diseases.

A composition comprising an expanded population of cells can be used in therapy, wherein the cells have been expanded by a method comprising: i) obtaining an isolated population of HSPCs; ii) culturing the isolated population of HSPCs in the presence of a histone deacetylase inhibitor (HDAC inhibitor) to form a cultured population; iii) adding to the cultured HSPC population an aminothiol compound having the formula RNH (CnH2n) NH (CnH2n) SX wherein R is hydrogen, an aryl group, an acyl group or an alkyl group containing from 1 to 7 carbon atoms, each n having a value of from 2 to 6, and X is H or PO3H2 to form expanded cells; or a pharmaceutically acceptable salt thereof.

The invention relates to the technical field of collagen, and discloses a preparation method of recombinant engineering bacteria for expressing III-type collagen COL17A1, which comprises the following steps: synthesizing an optimized sequence of human III-type collagen, and adding proper restriction enzyme cutting sites at two ends of the sequence. According to the preparation method of the recombinant engineering bacterium for expressing the III-type collagen COL17A1, codon optimization is carried out on a target sequence by adopting a yeast expression system, OptimGeneTM codon optimization is provided according to codon preference of yeast strains such as pichia pastoris, and the yield of recombinant protein is further improved. And a proper vector is selected to realize high-efficiency expression in pichia pastoris. For example, a pGAPZ A-alpha A vector stably expresses recombinant protein in pichia pastoris by using a GAP promoter, is a constitutive gene expression vector, and can maintain a stable expression rate in cells no matter how the environment changes. An inducer does not need to be added, the production process is simplified, the production cost is reduced, and the production efficiency is improved.

The invention discloses a swine fever and porcine parvovirus bivalent subunit vaccine and a preparation method thereof. The vaccine comprises a first recombinant protein encoded by a first gene, a second recombinant protein encoded by a second gene and a pharmaceutically acceptable carrier. The first gene has a sequence as shown in SEQ ID NO: 1 or an increased or reduced sequence thereof. And the second gene has a sequence as shown in SEQ ID NO: 2 or an increased or reduced sequence thereof. An antigen E2 protein of a hog cholera virus (CSFV) and a VP2 protein of a porcine parvovirus (PPV) are taken as double targets, a recombinant SC-E2 protein with a SpyCatcher tag and a recombinant ST-VP2 protein with a SpyTag tag are respectively expressed in insect cells through a recombinant baculovirus vector, double-antigen covalent assembly is realized in vitro, and the constructed bivalent subunit vaccine can be used for simultaneously preventing and controlling two epidemic diseases and has a good application prospect. And the vaccine has the advantages of high safety, strong immunogenicity, high prevention and control efficiency, easiness in large-scale production and the like.